Literature DB >> 10411702

Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure.

B Hoppe1, M J Kemper, A Bökenkamp, A A Portale, R A Cohn, C B Langman.   

Abstract

BACKGROUND: Children with primary hyperoxaluria type 1 (PH 1) are at great risk to develop systemic oxalosis in end-stage renal disease (ESRD), as endogenous oxalate production exceeds oxalate removal by dialytic therapy. As oxalate accumulates, calcium oxalate (CaOx) tissue deposition occurs. Children with other causes of ESRD, however, are not prone to CaOx deposition despite elevated plasma oxalate (POx) levels.
METHODS: Our study objective was to examine the potential mechanisms for these observations. We measured POx, sulfate, citrate, and calculated CaOx saturation (betaCaOx) in 7 children with ESRD caused by PH 1 and in 33 children with non-PH-related ESRD. Maintenance hemodialysis (HD) was performed in 6 PH 1 and 22 non-PH patients: Pre- and post-HD levels were analyzed at this point and were repeated twice within 12 months in 5 PH 1 and 14 non-PH patients. Samples were obtained only once in 12 patients (one PH 1) on peritoneal dialysis (PD). After liver-kidney or kidney transplantation, plasma levels were measured repetitively.
RESULTS: The mean POx was higher in PH 1 (125.7 +/- 17.9 micromol/liter) than in non-PH patients (44.2 +/- 3.3 micromol/liter, P < 10(-4)). All other determined anions did not differ between the two groups. betaCaOx was higher in PH 1 (4.71 +/- 0.69 relative units) compared with non-PH children (1.56 +/- 0.12 units, P < 10(-4)). POx and betaCaOx were correlated in both the PH 1 (r = 0.98, P < 2 x 10(-4)) and the non-PH group (r = 0.98, P < 10(-4)). POx and betaCaOx remained stable over time in the non-PH children, whereas an insignificant decline was observed in PH 1 patients after six months of more aggressive dialysis. betaCaOx was supersaturated (more than 1) in all PH 1 and in 25 out of 33 non-PH patients. Post-HD betaCaOx remained more than 1 in all PH 1, but in only 2 out of 22 non-PH patients. In non-PH children, POx and betaCaOx decreased to normal within three weeks after successful kidney transplantation, whereas the levels still remained elevated seven months after combined liver-kidney transplantation in two PH 1 patients.
CONCLUSION: Systemic oxalosis in PH 1 children with ESRD is due to higher POx and betaCaOx levels. As betaCaOx remained supersaturated in PH 1 even after aggressive HD, oxalate accumulation increases, and CaOx tissue deposition occurs. Therefore, sufficient reduction of POx and betaCaOx is crucial in PH 1 and might only be achieved by early, preemptive, combined liver-kidney transplantation or liver transplantation alone.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411702     DOI: 10.1046/j.1523-1755.1999.00546.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  35 in total

1.  Bone oxaloma-a localized manifestation of bone oxalosis.

Authors:  Eun Ji Choi; Choong Guen Chee; Wanlim Kim; Joon Seon Song; Hye Won Chung
Journal:  Skeletal Radiol       Date:  2019-11-25       Impact factor: 2.199

2.  The oxalate level in ultrafiltrate fluid collected from a dialyzer is useful for estimating the plasma oxalate level in hemodialysis patients.

Authors:  Makoto Ogi; Ryoetsu Abe; Tomohito Nishitani; Masanori Wakabayashi; Tsunemichi Wakabayashi
Journal:  Clin Exp Nephrol       Date:  2006-06       Impact factor: 2.801

3.  Calcium oxalate saturation in dialysis patients with and without primary hyperoxaluria.

Authors:  Yoshihide Ogawa; Noriko Machida; Tomohide Ogawa; Masami Oda; Sanehiro Hokama; Yoshiaki Chinen; Atsushi Uchida; Makoto Morozumi; Kimio Sugaya; Yaeko Motoyoshi; Motofumi Hattori
Journal:  Urol Res       Date:  2006-01-24

Review 4.  Primary hyperoxaluria type 1: still challenging!

Authors:  Pierre Cochat; Aurélia Liutkus; Sonia Fargue; Odile Basmaison; Bruno Ranchin; Marie-Odile Rolland
Journal:  Pediatr Nephrol       Date:  2006-06-30       Impact factor: 3.714

5.  End Points for Clinical Trials in Primary Hyperoxaluria.

Authors:  Dawn S Milliner; Tracy L McGregor; Aliza Thompson; Bastian Dehmel; John Knight; Ralf Rosskamp; Melanie Blank; Sixun Yang; Sonia Fargue; Gill Rumsby; Jaap Groothoff; Meaghan Allain; Melissa West; Kim Hollander; W Todd Lowther; John C Lieske
Journal:  Clin J Am Soc Nephrol       Date:  2020-03-12       Impact factor: 8.237

6.  Educational review: role of the pediatric nephrologists in the work-up and management of kidney stones.

Authors:  Carmen Inés Rodriguez Cuellar; Peter Zhan Tao Wang; Michael Freundlich; Guido Filler
Journal:  Pediatr Nephrol       Date:  2019-01-04       Impact factor: 3.714

7.  Oxalate quantification in hemodialysate to assess dialysis adequacy for primary hyperoxaluria.

Authors:  Xiaojing Tang; Nikolay V Voskoboev; Stacie L Wannarka; Julie B Olson; Dawn S Milliner; John C Lieske
Journal:  Am J Nephrol       Date:  2014-04-26       Impact factor: 3.754

Review 8.  Oxalate, inflammasome, and progression of kidney disease.

Authors:  Theresa Ermer; Kai-Uwe Eckardt; Peter S Aronson; Felix Knauf
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-07       Impact factor: 2.894

9.  Plasma oxalate level in pediatric calcium stone formers with or without secondary hyperoxaluria.

Authors:  Przemysław Sikora; Bodo Beck; Małgorzata Zajaczkowska; Bernd Hoppe
Journal:  Urol Res       Date:  2009-01-30

10.  Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure.

Authors:  Fang Zhao; Eric J Bergstralh; Ramila A Mehta; Lisa E Vaughan; Julie B Olson; Barbara M Seide; Alicia M Meek; Andrea G Cogal; John C Lieske; Dawn S Milliner
Journal:  Clin J Am Soc Nephrol       Date:  2015-12-10       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.